Ragon Institute Study Maps the Success of LACTIN-V: How Live Biotherapeutics Reshape the Vaginal Microbiome to Prevent Recurrence

New 2026 research reveals how LACTIN-V reshapes the vaginal microbiome and why initial bacterial levels predict treatment success in millions of women.

By: AXL Media

Published: Mar 28, 2026, 4:55 AM EDT

Source: Information for this report was sourced from the Ragon Institute of MGH, MIT and Harvard.

The Challenge of Persistent Bacterial Vaginosis

Bacterial Vaginosis (BV) is the most prevalent vaginal condition globally, affecting more than 25% of women of reproductive age. While standard antibiotics like metronidazole effectively clear initial infections, the recurrence rate is alarmingly high, with over 50% of women experiencing a return of symptoms within a year. This cycle is often caused by the failure of the vaginal microbiome to re-establish a protective layer of Lactobacillus crispatus, a "beneficial" bacterium that maintains low pH and wards off pathogens.

LACTIN-V: A Living Solution

To break this cycle, researchers developed LACTIN-V, a live biotherapeutic product (LBP) containing a specific strain of L. crispatus. In clinical trials, LACTIN-V significantly outperformed placebos in preventing recurrence. However, the benefits were not universal; roughly 30% of women still saw the condition return. The recent study published in Cell Host & Microbe analyzed 1,100 samples from 213 participants to determine what separates a successful "colonization" from a failed one.

Key Findings: Who Benefits Most?

The research team discovered that 12 weeks into the treatment, 30% of women receiving LACTIN-V achieved a healthy, L. crispatus-dominant microbiome, compared to just 9% in the placebo group. Interestingly, the study found that the "starting state" of a woman's microbiome was the strongest predictor of success: